Company: BIVIW
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001520138-25-000144
Chunk: 42

Company: BIOVIE INC.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 1
Chunk 42
---
,572 
  
    Liver Program Phase 3 
     135,888  
     39,880  
     96,008 
  
    Long Covid Program, net of $2.8 million reimbursement 
     1,313,294  
     -  
     1,313,294 
  
    Investigator-Initiated studies 
     24,763  
     9,199  
     15,564 

    $4,114,517  
    $69,079  
    $4,045,438 

    Completed Studies 

    Ascites BIV201 Phase 2b 
    $(63,773) 
    $595,014  
    $(658,787)
  
    AD mild to moderate pivotal Phase 3 
     18,034  
     9,051,902  
     (9,033,868)
  
    PD Phase 2 
     -  
     601,080  
     (601,080)
  
     Investigator-Initiated studies 
     -  
     88,986  
     (88,986)
  
    Other studies in development/canceled 
     18,253  
     1,275,422  
     (1,257,169)

    $(27,486) 
    $11,612,404  
    $(11,639,890)

 25 

Selling, General and Administrative Expenses

Selling, general and administrative expenses for the
nine months ended March 31, 2025, was approximately $6.2 million and was comparable to approximately $6.2 million for the nine months
ended March 31, 2024. The net fluctuations in expenses were primarily comprised of decreases in directors’ compensation of approximately
$339,000, executive teams’ compensation of approximately $416,000, investor and public relation fees of $131,000 offset by increases
in other professional and consultancy fees of $566,000, legal fees of approximately $255,000, audit and accounting fees of approximately
$72,000, and insurance premiums of approximately $31,000.

Other Income and Expense

Other income, net was approximately $350,000 for the
nine months ended March 31, 2025, compared to approximately $210,000 for the nine months ended March 31, 2024. The